Atlanta Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Atlanta Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-509,660	Closed	-$8.39M	–	205
2014 Q4	$8.39M	Sell	509,660 -578,052	-53%	-$9.92M	0.06%	164
2014 Q3	$19.2M	Sell	1,087,712 -11,620	-1%	-$228K	0.14%	142
2014 Q2	$22.7M	Sell	1,099,332 -16,195	-1%	-$333K	0.16%	134
2014 Q1	$24.3M	Buy	1,115,527 +15,941	+1%	+$365K	0.17%	135
2013 Q4	$29.2M	Sell	1,099,586 -5,927	-0.5%	-$146K	0.19%	128
2013 Q3	$26.1M	Buy	1,105,513 +12,792	+1%	+$299K	0.19%	126
2013 Q2	$23.5M	Buy	+1,092,721	New	+$23.6M	0.18%	125

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

CPCM

Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

Atlanta Capital Management's VIVO Position: Q1 2015 in Review

Atlanta Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2015, closing a stake of 509,660 shares — an estimated $8.39M sold.

Atlanta Capital Management first reported a position in VIVO in Q2 2013 and held it in 7 quarters. The position peaked at $29.2M in Q4 2013. 159 funds tracked by Wall St. Rank hold VIVO as of Q1 2015.

Atlanta Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2015 after selling out during the quarter.
Atlanta Capital Management sold 509,660 Meridian Bioscience Inc shares in Q1 2015, an estimated $8.39M.
Atlanta Capital Management first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 7 quarters.
Atlanta Capital Management's Meridian Bioscience Inc position peaked at $29.2M in Q4 2013.
159 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2015.

Based on Atlanta Capital Management's 13F filing for Q1 2015, filed 14 May 2015.